Table 3

Characteristics of complete responders

CharacteristicClofarabine, ratio (%)Clofarabine plus LD cytarabine, ratio (%)Total, ratio. (%)P
Overall number of patients 5/16 (31) 34/54 (63) 39/70 (56) .025 
Karyotype     
    Diploid 2/6 (33) 21/27 (78) 23/33 (70) .053 
    Abnormal 3/8 (38) 13/27 (48) 16/35 (46) .07 
        −5/−7 1/2 (50) 6/14 (43) 7/16 (44)  
        +8 0/1 2/4 (50) 2/5 (40)  
        del(11)(q23)  1/1 (100) 1/1 (100)  
        Not available/IM 0/2  0/2  
Flt3 status     
    No abnormality 5/11 (45) 31/44 (70) 36/55 (65) .161 
    Abnormal 0/2 2/6 (33) 2/8 (25)  
        ITD 0/2 1/5 (20)* 1/7 (14)  
        D835  2/3 (67)* 2/3 (67)  
Secondary AML     
    Yes 2/7 (29) 15/28 (54) 17/35 (49) .402 
    Yes with diploid karyotype 0/1 8/12 (67) 8/13 (62)  
    No 3/9 (33) 19/26 (73) 22/35 (63) .051 
    No with diploid karyotype 1/4 (25) 11/14 (79) 12/18 (67) .083 
Age, y     
    60 to 64 1/1 (100) 7/9 (78) 8/10 (80)  
    65 to 69 2/4 (50) 13/16 (81) 15/20 (75) .249 
    Older than 70 2/11 (18) 14/29 (48) 16/40 (40) .148 
CharacteristicClofarabine, ratio (%)Clofarabine plus LD cytarabine, ratio (%)Total, ratio. (%)P
Overall number of patients 5/16 (31) 34/54 (63) 39/70 (56) .025 
Karyotype     
    Diploid 2/6 (33) 21/27 (78) 23/33 (70) .053 
    Abnormal 3/8 (38) 13/27 (48) 16/35 (46) .07 
        −5/−7 1/2 (50) 6/14 (43) 7/16 (44)  
        +8 0/1 2/4 (50) 2/5 (40)  
        del(11)(q23)  1/1 (100) 1/1 (100)  
        Not available/IM 0/2  0/2  
Flt3 status     
    No abnormality 5/11 (45) 31/44 (70) 36/55 (65) .161 
    Abnormal 0/2 2/6 (33) 2/8 (25)  
        ITD 0/2 1/5 (20)* 1/7 (14)  
        D835  2/3 (67)* 2/3 (67)  
Secondary AML     
    Yes 2/7 (29) 15/28 (54) 17/35 (49) .402 
    Yes with diploid karyotype 0/1 8/12 (67) 8/13 (62)  
    No 3/9 (33) 19/26 (73) 22/35 (63) .051 
    No with diploid karyotype 1/4 (25) 11/14 (79) 12/18 (67) .083 
Age, y     
    60 to 64 1/1 (100) 7/9 (78) 8/10 (80)  
    65 to 69 2/4 (50) 13/16 (81) 15/20 (75) .249 
    Older than 70 2/11 (18) 14/29 (48) 16/40 (40) .148 

Ratios are complete responders per number in group or subgroup.

LD indicates low-dose; IM, insufficient metaphases; ITD, internal tandem duplication; and D835, amino acid mutation at codon aspartate 835.

*

Two patients with both ITD and D835.

Close Modal

or Create an Account

Close Modal
Close Modal